BRAF

Liquid Biopsy to Detect BRAFV600 Mutations in Advanced Cancers Shows Promise

Liquid Biopsy to Detect BRAFV600 Mutations in Advanced Cancers Shows Promise

By

Investigators found that cell-free DNA is released into circulation by cancer cells undergoing apoptosis or necroptosis in the primary or metastatic cancer lesions.

BRAF mutations in non-small cell lung cancer

BRAF mutations in non-small cell lung cancer

[Translational Lung Cancer Research] This research investigates the prevalence and clinicopathological features of BRAF mutations in non-small cell lung cancer (NSCLC) cases submitted for routine mutation testing.

For Melanoma, Pretreatment Influences Vemurafenib Therapy Outcomes

For Melanoma, Pretreatment Influences Vemurafenib Therapy Outcomes

Type of pretreatment greatly influences vemurafenib therapy outcomes for patients with BRAF V600 mutated melanoma.

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma

By

Update on available treatment options and potential future developments for metastatic melanoma with and without BRAF mutations.

Nivolumab + Ipilimumab: 'Unprecedented' Survival Rates in Advanced Melanoma

Nivolumab + Ipilimumab: 'Unprecedented' Survival Rates in Advanced Melanoma

By

CHICAGO, IL—Concurrent treatment with nivolumab plus ipilimumab resulted in "unprecedented" 2-year rates of overall survival in patients with advanced melanoma regardless of BRAF-mutation status.

Risk for New Primaries Higher in Stage III/IV Melanoma

Risk for New Primaries Higher in Stage III/IV Melanoma

Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas.

FDA Approves Trametinib/Dabrafenib Combination

FDA Approves Trametinib/Dabrafenib Combination

By

The FDA has approved the use of trametinib in combination with dabrafenib for treatment of some types of melanoma.

BRAF Mutation May Increase Thyroid Cancer Death

BRAF Mutation May Increase Thyroid Cancer Death

Retrospective multicenter study shows PTC-related mortality increased with mutation

Targeting BRAF Mutation in Melanoma Treatment

Targeting BRAF Mutation in Melanoma Treatment

By

Advanced, metastatic melanoma is an aggressive disease with a poor prognosis; but therapies targeting gene mutations may offer hope to some patients.

Novel ERK Inhibitor Shows Preclinical Promise Against BRAF, MEK-associated Drug Resistance

By

SCH772984 shows promise against tumor growth driven by BRAF and RAS mutations and might prove useful against tumor resistance to BRAF and MEK inhibitors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs